NIH-supported researchers develop novel system to grow norovirus in intestinal cells

August 25, 2016


Researchers have succeeded in culturing norovirus in human intestinal cells, a breakthrough that could help scientists develop novel therapeutics and vaccines against the debilitating effects of the virus. Intestinal cells are the natural site of norovirus infection, a leading cause of foodborne illness that is highly contagious and can produce sudden onset stomach pain, nausea, diarrhea and vomiting. In the United States, norovirus infection results in about 400,000 emergency department visits and as many as 71,000 hospitalizations annually, mostly among young children and the elderly, according to the U.S. Centers for Disease Control and Prevention. The virus spreads easily in closed and crowded environments such as hospitals, schools and cruise ships.

Norovirus was first identified in 1972 at the National Institutes of Health (NIH) by Albert Z. Kapikian, M.D., and colleagues. However, study of the virus has been difficult because of researchers' inability to grow the virus outside the human body and the lack of a good animal model to study infection and disease. This has limited knowledge of the basic biology of the virus, including aspects of the molecular mechanisms behind how it causes people to become ill.

To overcome this gap, investigators at Baylor College of Medicine engineered human intestinal tissue from stem cells isolated from the small intestine. When the researchers infected the cultured gut tissue with different strains of norovirus, some virus strains grew well in the cells while others did not. To promote virus growth, the team then tried adding bile from humans and other animals, including cows and pigs, to the intestinal cells. Researchers found that bile was required for replication of some virus strains and enhanced the growth of other strains in the cells. The authors say this new cultivation method could have applications for food safety and the development of new diagnostics, vaccines and therapeutics for norovirus.
Findings from the research, which was supported in part by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, appear in the current issue of the journal Science.


K Ettayebi et al. Replication of human noroviruses in stem cell-derived human enteroids. Science DOI: 10.1126/science.aaf5211 (2016).


NIAID Director Anthony S. Fauci, M.D., and Rodolfo Alarcon, Ph.D., Program Officer, Enteric Viruses, NIAID's Division of Microbiology and Infectious Diseases, are available for comment.


To schedule interviews, please contact Emily Mullin, (301) 402-1663,

NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit Discovery Into Health®

NIH/National Institute of Allergy and Infectious Diseases

Related Vaccines Articles from Brightsurf:

Safety of HPV vaccines in males
A new analysis published in the British Journal of Clinical Pharmacology shows that HPV vaccines are safe and well tolerated in the male population, and the side effects that may occur after immunization are similar in both sexes.

Model could improve design of vaccines, immunotherapies
Researchers have discovered a general property for understanding how immune cell receptors sense and respond to microbial signals, which could lead to more effective vaccines for both existing and novel viruses.

Better vaccines are in our blood
Red blood cells don't just shuttle oxygen from our lungs to our organs: they also help the body fight off infections by capturing pathogens in the blood and presenting them to immune cells in the spleen.

Challenges in evaluating SARS-CoV-2 vaccines
With more than 140 SARS-CoV-2 vaccines in development, the race is on for a successful candidate to help prevent COVID-19.

Designing vaccines from artificial proteins
EPFL scientists have developed a new computational approach to create artificial proteins, which showed promising results in vivo as functional vaccines.

Misinformation on vaccines readily available online
Parents researching childhood vaccinations online are likely to encounter significant levels of negative information, researchers at the University of Otago, Wellington, have found.

Battle with the cancer: New avenues from childhood vaccines
A new research from the University of Helsinki showed for the first time how the pre-immunization acquired through common childhood vaccines can be used to enhance therapeutic cancer treatment.

Personalized cancer vaccines
The only therapeutic cancer vaccine available on the market has so far showed very limited efficacy in clinical trials.

Doubts raised about effectiveness of HPV vaccines
A new analysis of the clinical trials of HPV vaccines to prevent cervical cancer raises doubts about the vaccines' effectiveness.

Egg-based flu vaccines: Not all they're cracked up to be?
Flu season is underway in the Northern Hemisphere, sickening millions of people and in rare cases, causing hospitalization or death.

Read More: Vaccines News and Vaccines Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to